Functional evaluation of NK<sub>1</sub> antagonism on cue reactivity in opiate dependence; An fMRI study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 33548897.
- Also identified by DOI 10.1016/j.drugalcdep.2021.108564 and PMC identifier 8047866.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Opiate addiction is a major health challenge with substantial societal cost. Though harm minimisation strategies have been effective, there is a growing need for new treatments for detoxification and relapse prevention. Preclinical research has found neurokinin 1 (NK<sub>1</sub>) receptors have prominent effects on opiate reward and reinforcement, and human studies have found NK<sub>1</sub> antagonism led to reductions in craving and withdrawal. However, its effect on brain mechanisms in opiate addiction has not yet been examined. This study aims to assess the impact of NK<sub>1</sub> antagonist aprepitant on heroin cue-elicited changes in blood-oxygenation level dependent (BOLD) signal in opiate dependent individuals undergoing detoxification. Participants will attend two scanning sessions and receive a single dose of aprepitant (320 mg) and a placebo in a randomised, cross-over design. During functional magnetic resonance imaging participants will undergo two runs of a cue reactivity task, which consists of passive viewing of drug cues or neutral cues in a block design fashion. We hypothesise that NK<sub>1</sub> antagonism will attenuate the BOLD response to drug cues in the caudate nucleus and amygdala. Regions of interest were selected based on NK<sub>1</sub> receptor density and their role in cue reactivity and craving.
Medical subject headings
- Neurokinin-1 Receptor Antagonists
- Opioid-Related Disorders